<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04743063</url>
  </required_header>
  <id_info>
    <org_study_id>2019P000110-ARNI</org_study_id>
    <nct_id>NCT04743063</nct_id>
  </id_info>
  <brief_title>Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty</brief_title>
  <official_title>Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to establish a near-real-time prospective monitoring program&#xD;
      in Medicare, Optum and MarketScan Research data to evaluate the benefit of new cardiovascular&#xD;
      disease (CVD) drugs for older adults with frailty. Prospective monitoring program seeks to&#xD;
      find early effectiveness and safety signals of new drugs by updating the analysis at regular&#xD;
      intervals as new Medicare data become available. This study specifically aims to emulate a&#xD;
      prospective surveillance of the effectiveness and safety of Angiotensin Receptor Neprilysin&#xD;
      Inhibitor(ARNI) vs. a comparator, Angiotensin II Receptor Blockers (ARBs), in older adults&#xD;
      with Heart Failure with Reduced Ejection Fraction (HFrEF) and different frailty status. This&#xD;
      program will be enhanced by incorporating a novel claims-based frailty index, which has been&#xD;
      shown useful in assessing how the benefits and harms of drug therapy vary by frailty.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data sources of use for this study are: Medicare Database, Optum Database, and MarketScan&#xD;
      Research Database. All data from years 2014-2020 will be included in the study.&#xD;
&#xD;
      This study follows a sequential cohort monitoring design. The monitoring analysis will&#xD;
      include 1) retrospective analysis of available data (2015-2017) at the time of first analysis&#xD;
      (January 2021) and 2) prospective analysis of new data (2018-2020) as they become available&#xD;
      to the researchers. Within each database, we will emulate biannual updating of data by&#xD;
      creating a propensity score (PS)-matched cohort of new users every 6-month interval,&#xD;
      beginning on the first marketing of ARNI (July 7, 2015-December 31, 2015, and 6-month&#xD;
      intervals afterwards). Each sequential cohort will be followed for development of the&#xD;
      outcomes of interest. Outcome analysis will be performed at a pre-specified 6-month interval&#xD;
      (prospective analysis). The surveillance will be performed by frailty status (frail vs&#xD;
      non-frail) at the time of drug initiation. The results from each database will be pooled&#xD;
      using fixed-effects meta-analysis (assuming low heterogeneity across the databases).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 14, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with composite events of death or heart failure hospitalization</measure>
    <time_frame>July 2015 - December 2020</time_frame>
    <description>All-cause mortality OR heart failure hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with composite serious adverse events</measure>
    <time_frame>July 2015 - December 2020</time_frame>
    <description>Hypotension OR acute kidney injury/acute kidney failure OR hyperkalemia OR angioedema</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with all-cause mortality</measure>
    <time_frame>July 2015 - December 2020</time_frame>
    <description>All-cause mortality is defined by the National Death Index file or vital status information in the claims dataset.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with heart failure hospitalization</measure>
    <time_frame>July 2015 - December 2020</time_frame>
    <description>Heart failure hospitalization is defined as any hospitalization with relevant diagnosis codes in the primary position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with hypotension</measure>
    <time_frame>July 2015 - December 2020</time_frame>
    <description>Hypotension is defined as any hospitalization or Emergency Department visit with relevant diagnosis codes in the primary position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with hyperkalemia</measure>
    <time_frame>July 2015 - December 2020</time_frame>
    <description>Hyperkalemia is defined as any hospitalization or Emergency Department visit with relevant diagnosis codes in the primary position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with acute kidney injury/acute kidney failure</measure>
    <time_frame>July 2015 - December 2020</time_frame>
    <description>Acute kidney injury/Acute kidney failure is defined as any hospitalization or Emergency Department visit with relevant diagnosis codes in the primary position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with angioedema</measure>
    <time_frame>July 2015 - December 2020</time_frame>
    <description>Angioedema is defined as any hospitalization or Emergency Department visit with relevant diagnosis codes in the primary position.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40000</enrollment>
  <condition>Heart Failure, Systolic</condition>
  <condition>Frailty</condition>
  <arm_group>
    <arm_group_label>New users of angiotensin receptor neprilysin inhibitor</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>New users of angiotensin II receptor blockers</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sacubitril/valsartan</intervention_name>
    <description>Initiation of sacubitril/valsartan, identified using prescription fill in pharmacy claims</description>
    <arm_group_label>New users of angiotensin receptor neprilysin inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin II Receptor Blockers</intervention_name>
    <description>Initiation of ARBs, identified using prescription fill in pharmacy claims</description>
    <arm_group_label>New users of angiotensin II receptor blockers</arm_group_label>
    <other_name>azilsartan</other_name>
    <other_name>candesartan</other_name>
    <other_name>eprosartan</other_name>
    <other_name>Irbesartan</other_name>
    <other_name>losartan</other_name>
    <other_name>Olmesartan</other_name>
    <other_name>telmisartan</other_name>
    <other_name>valsartan</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study population includes older patients with heart failure with reduced ejection fraction&#xD;
        who initiates an angiotensin receptor neprilysin inhibitor or an angiotensin II receptor&#xD;
        blocker.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Continuous enrollment for medical and drug insurance (e.g., Medicare Part A, B, and D)&#xD;
             in [-365, 0] days&#xD;
&#xD;
          -  Diagnosis of Heart Failure either two outpatient diagnosis or one inpatient diagnosis&#xD;
             in [-365, 0] days&#xD;
&#xD;
          -  Reduced Ejection Fraction &lt; 45% identified using a validated claims-based algorithm in&#xD;
             [-365, 0] days&#xD;
&#xD;
               -  Day 0 is the initiation date of the study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No prior use of Angiotensin receptor neprilysin inhibitor or angiotensin II receptor&#xD;
             blocker in [-365, -1] days&#xD;
&#xD;
          -  No recent HF hospitalization, defined as HF diagnosis (defined in attached protocol)&#xD;
             in the primary position in the inpatient dataset in [-60, 0] days&#xD;
&#xD;
          -  No recent nursing facility stay (defined in attached protocol) for [-60, 0] days&#xD;
&#xD;
          -  Age &lt; 65 years&#xD;
&#xD;
          -  Exposure to both drugs on day 0&#xD;
&#xD;
          -  Contraindication to either drug (exclusion assessment window: [-60, 0] days, unless&#xD;
             specified otherwise; algorithms specified in attached protocol)&#xD;
&#xD;
        Note: If a patient meets the above-mentioned eligibility criteria more than once, only the&#xD;
        first record will be included.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae Hyun Kim, MD, MPH, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham And Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Dae Hyun Kim, MD, MPH, ScD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
    <mesh_term>Frailty</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Eprosartan</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Giapreza</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 11, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT04743063/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

